L’Oréal and Light BioScience sign collaboration agreement for the development of skincare devices

L’Oréal, the world’s largest beauty company, and Light BioScience, LLC, of Virginia Beach, Virginia, leader in the medical research of LED (Light Emitting Diodes) Photomodulation® have signed a scientific collaboration agreement for the development of skincare devices using Light BioScience’s proprietary skin rejuvenation technology. The agreement also provides for future worldwide marketing by L’Oréal of professional devices already developed by Light BioScience to reduce the visible signs of aging.

Light BioScience produces the GentleWaves® LED Photomodulation® medical device, used by physicians and medical spas around the world to reduce wrinkles and improve skin. LED Photomodulation® is a non-invasive technology which stimulates the skin using low intensity LEDs. This gentle method of skin rejuvenation with light has been shown to be safe and effective and the technology is protected by numerous patents.

Jean-François Grollier, L’Oreal’s Executive Vice-President Research and Development, said: "We have decided to pool our in-depth knowledge of skin and Light BioScience’s unique expertise in Photomodulation® to offer consumers a new and complementary approach to skincare."

With this aim in mind, L’Oréal has just created a Development Unit for instrumental cosmetics inside its Research and Development Division.

Rick Krupnick, Chief Executive Officer of Light BioScience, and David H. McDaniel MD, the physician who developed the scientific theory behind Photomodulation® added, "We are very excited about this agreement: we can take advantage of the support of the world's leading cosmetics research force to jointly develop some new and highly promising applications in skin devices."

"This news release does not constitute an offer to sell, or a solicitation of an offer to buy L'Oréal shares. If you wish to obtain more comprehensive information about L'Oréal, please refer to the public documents registered in France with the Autorité des Marchés Financiers also available in English on our Internet site www.loreal-finance.com.
This news release may contain some forward-looking statements. Although the Company considers that these statements are based on reasonable hypotheses at the date of publication of this release, they are by their nature subject to risks and uncertainties which could cause actual results to differ materially from those indicated or projected in these statements."

Individual shareholders and market authorities
Mr Jean-Régis CAROF
Tel. : +33.1.47.56.83.02
jcarof@dgaf.loreal.com

Financial analysts and institutional investors
Mrs Caroline MILLOT
Tel. : +33.1.47.56.86.82
cmillot@dgaf.loreal.com

Journalists
Mr Mike RUMSBY
Tel. : +33.1.47.56.41.95
http://www.loreal.com

Switchboard
Tél: +33.1.47.56.70.00

Contacts at LIGHT BIOSCIENCE

Carolyn Marquez
Tel: +1 888.647.6219
carolynmarquez@optonline.net

For more information, please contact your bank, broker or financial institution (I.S.I.N. code: FR0000120321), and consult your usual newspapers, and the Internet site for shareholders and investors, http://www.loreal-finance.com, or its mobile version on your cell phone, http://mobile.loreal-finance.com.